CLINICAL ASSESSMENT OF AN INTEGRATIVE THERAPEUTIC APPROACH USING LIV IMMUNE CAPSULES IN PATIENTS WITH FATTY LIVER AND DYSLIPIDEMIA: AN OPEN-LABEL CLINICAL STUDY

Background: non-alcoholic fatty liver disease (grade 1–2) and hypercholesterolemia/dyslipidemia are common metabolic conditions, coexisting with fatigue, and constipation. There is increasing interest in integrative ayurvedic approaches combining herbal formulations with diet and yoga for hepatic and lipid metabolic support. Aim: to evaluate the clinical outcomes of liv immune capsules, combined with a personalized diet and structured yoga protocol, on liver status (ultrasonographic grading), lipid profile (total cholesterol, ldl, triglycerides), and associated symptoms (fatigue, constipation) in patients presenting with fatty liver and/or dyslipidemia. Materials and Methods: an open-label, clinical study was conducted over a duration of 3 months involving 15 patients (n=15, age range 18–79 years) presenting with grade 1–2 fatty liver and/or hypercholesterolemia/dyslipidemia, associated with or without fatigue or constipation. Patients received liv immune capsules (2–0–2) along with an individualized diet plan and a structured yoga protocol. Assessment was based on pre- versus post-treatment lipid profile and, where available, pre- versus post-treatment liver ultrasonography. Results: a total of 15 patients were included in the study. Hypercholesterolemia/dyslipidemia was present in 6 patients, all of whom demonstrated improvement in one or more lipid parameters (total cholesterol, ldl cholesterol, and/or triglycerides) following treatment. Fatty liver on ultrasonography was evaluated in 8 patients; follow-up usg revealed complete resolution in 3 patients, measurable improvement in 4 patients, and no radiological change in 1 patient. Fatigue was reported by 5 patients, of whom 4 showed clinical improvement, while constipation resolved completely in the four affected patient. Conclusion: the integrative protocol of liv immune capsules with personalized diet and yoga was associated with consistent improvement in lipid parameters and variable improvement in fatty liver imaging findings, along with symptomatic relief in several patients. As a retrospective case series with a small, heterogeneous sample and non-uniform follow-up duration, the findings are preliminary and support the design of a prospective, standardized clinical study.

• Sushruta. Sushruta Samhita, Sutra Sthana: Yakrit (liver) anatomy and Medoroga description [classical text].
• Charaka. Charaka Samhita, Chikitsa Sthana: Udara Roga and Medoroga chapters [classical text].
• Vagbhata. Ashtanga Hridaya: Agni, Ama, and Meda Dhatu physiology [classical text].
• Kumar S. The role of Ayurvedic management in non-alcoholic fatty liver disease (NAFLD): a case study. Int J Complement Alt Med., 2024; 17(2): 103-5.
• Aggarwal D, Soni RK. Ayurveda management against non-alcoholic fatty liver disease: a case report. J Ayurveda Integr Med Sci., 2024.
• Reviving liver health with Ayurveda: a systematic review of non-alcoholic fatty liver disease management. Int J Res Med Sci., 2025.
• Ayurvedic management of non-alcoholic fatty liver disease with obesity and rheumatoid arthritis: a case report. ScienceDirect, 2025.
• Effect of Ayurveda interventions in non-alcoholic grade II fatty liver associated with obesity: a case report. PMID: 35868134.
• Bhatt N, Deshpande M. A review of Siddha traditional system products and their ingredients in liver diseases. Int J AYUSH, 2020.
• Gupta R, Rao RS, Misra A, Sharma SK. Recent trends in epidemiology of dyslipidemias in India. Indian Heart J., 2017; 69(3): 382-92.
• ICMR-INDIAB Study Group. Prevalence of dyslipidemia in urban and rural India: the ICMR-INDIAB study. PLoS One. 2014.
• Ghazvineh D, Daneshvar M, Basirat V, Daneshzad E. The effect of yoga on the lipid profile: a systematic review and meta-analysis of randomized clinical trials. Front Nutr., 2022; 9: 942702.
• Parker A, Kim Y. The effect of low glycemic index and glycemic load diets on hepatic fat mass, insulin resistance, and blood lipid panels in individuals with NAFLD. Metab Syndr Relat Disord, 2019; 17(8): 389-96.
• Karan D, Chakraborty A, Sinha J, et al. Hepatoprotective activity of Swertia chirata against paracetamol- and galactosamine-induced hepatotoxicity in rats. J Ethnopharmacol, 1999; 64(6): 621-7.
• Verma PC, Basu V, Gupta V, Saxena G, Rahman LU. Pharmacology and chemistry of a potent hepatoprotective compound picroliv isolated from the roots and rhizomes of Picrorhiza kurroa Royle ex Benth (kutki). Curr Pharm Biotechnol, 2009; 10(6): 641-9.
• Vaidya AB, Antarkar DS, Doshi JC, et al. Picrorhiza kurroa (kutaki) Royle ex Benth as a hepatoprotective agent: experimental and clinical studies. J Postgrad Med., 1996; 42(4): 105-8.